Literature DB >> 18549415

Distinguishing Parkinson's disease and essential tremor with transcranial sonography.

M Budisic1, Z Trkanjec, J Bosnjak, A Lovrencic-Huzjan, V Vukovic, V Demarin.   

Abstract

OBJECTIVES: Until today there is no reliable test that can clearly distinguish Parkinson's disease (PD) from the essential tremor (ET). Our aim was to determine the usefulness of the transcranial sonography (TCS) in the differential diagnosis of the PD and ET as well as the interobserver reliability for this method.
METHODS: Transcranial sonography of substantia nigra and clinical examination were performed on 80 PD patients, 30 ET patients, and 80 matched controls by two independent physicians.
RESULTS: Bilateral SN hyperechogenicity over the margin of 0.20 cm(2) was found in 91% of PD patients, 10% of healthy subjects, and in 13% patients with ET. Interobserver agreement for this method was significant (Student's t-test, P = 1.000).
CONCLUSIONS: Substantia nigra hyperechogenicity on TCS is a highly specific finding of PD, where in healthy individuals or in ET patients, it might correspond to an increased risk of developing PD later in life or might also be because of the impairment of nearby area of nucleus ruber in ET patients, as suggested by positron emission tomography studies. TCS may serve as a practical and sufficiently sensitive neuroimaging tool in PD diagnoses and in distinguishing it from ET; its repeatability and accuracy might add to its practical value.

Entities:  

Mesh:

Year:  2008        PMID: 18549415     DOI: 10.1111/j.1600-0404.2008.01056.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  19 in total

1.  Transcranial sonography on Parkinson's disease and essential tremor in a Chinese population.

Authors:  Wei-Feng Luo; Ying-Chun Zhang; Yu-Jing Sheng; Jun-Chu Fang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2011-12-11       Impact factor: 3.307

Review 2.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

3.  Essential tremor and Parkinson's disease: lack of a link.

Authors:  Charles H Adler; Holly A Shill; Thomas G Beach
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

4.  Essential tremor: is it a neurodegenerative disease? No.

Authors:  Monica M Kurtis
Journal:  J Neural Transm (Vienna)       Date:  2012-08-17       Impact factor: 3.575

Review 5.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 6.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

Review 7.  Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2010-09-10       Impact factor: 3.575

Review 8.  [Sonography of the parenchyma in Parkinson's disease].

Authors:  J Hagenah; G Seidel
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

9.  Brainstem raphe lesion in patients with major depressive disorder and in patients with suicidal ideation recorded on transcranial sonography.

Authors:  Mislav Budisic; Budisic Mislav; Dalibor Karlovic; Karlovic Dalibor; Zlatko Trkanjec; Trkanjec Zlatko; Arijana Lovrencic-Huzjan; Lovrencic-Huzjan Arijana; Vlasta Vukovic; Vukovic Vlasta; Jelena Bosnjak; Bosnjak Jelena; Vida Demarin; Demarin Vida
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-09-15       Impact factor: 5.270

Review 10.  Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review.

Authors:  Annemarie M M Vlaar; Angela Bouwmans; Werner H Mess; Selma C Tromp; Wim E J Weber
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.